Compare Stocks: TRDA, JANX, SANA, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$18.03 -4.0%	$16.12	$12.12 ▼ $35.34	$1.10B	2.5	698,921 shs	637,808 shs
KURA Kura Oncology	$12.66 -3.9%	$10.86	$7.36 ▼ $13.90	$1.13B	0.38	2.19 million shs	1.81 million shs
SANA Sana Biotechnology	$3.93 -3.9%	$3.57	$2.61 ▼ $6.55	$1.18B	2.16	2.53 million shs	2.14 million shs
TRDA Entrada Therapeutics	$7.00 -3.7%	$7.08	$5.02 ▼ $16.45	$272.56M	-0.26	306,888 shs	111,601 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	0.00%	+3.68%	+15.73%	+23.58%	-22.78%
KURA Kura Oncology	0.00%	+6.48%	+35.98%	+24.12%	+61.07%
SANA Sana Biotechnology	0.00%	+0.51%	+20.92%	+19.09%	+16.62%
TRDA Entrada Therapeutics	0.00%	-7.53%	+3.40%	-0.99%	+23.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$18.03 -4.0%	$16.12	$12.12 ▼ $35.34	$1.10B	2.5	698,921 shs	637,808 shs
KURA Kura Oncology	$12.66 -3.9%	$10.86	$7.36 ▼ $13.90	$1.13B	0.38	2.19 million shs	1.81 million shs
SANA Sana Biotechnology	$3.93 -3.9%	$3.57	$2.61 ▼ $6.55	$1.18B	2.16	2.53 million shs	2.14 million shs
TRDA Entrada Therapeutics	$7.00 -3.7%	$7.08	$5.02 ▼ $16.45	$272.56M	-0.26	306,888 shs	111,601 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	0.00%	+3.68%	+15.73%	+23.58%	-22.78%
KURA Kura Oncology	0.00%	+6.48%	+35.98%	+24.12%	+61.07%
SANA Sana Biotechnology	0.00%	+0.51%	+20.92%	+19.09%	+16.62%
TRDA Entrada Therapeutics	0.00%	-7.53%	+3.40%	-0.99%	+23.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	102.23% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.40	100.63% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	137.49% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	153.57% Upside

Current Analyst Ratings Breakdown

Latest TRDA, JANX, SANA, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JANX Janux Therapeutics	$10M	110.24	N/A	N/A	$15.18 per share	1.19
KURA Kura Oncology	$77.23M	14.58	N/A	N/A	$0.54 per share	23.44
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A
TRDA Entrada Therapeutics	$25.42M	10.72	N/A	N/A	$5.99 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest TRDA, JANX, SANA, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JANX Janux Therapeutics	N/A	16.35	16.35
KURA Kura Oncology	0.12	4.73	4.71
SANA Sana Biotechnology	N/A	1.38	1.38
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JANX Janux Therapeutics	75.39%
KURA Kura Oncology	N/A
SANA Sana Biotechnology	88.23%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
JANX Janux Therapeutics	7.90%
KURA Kura Oncology	7.60%
SANA Sana Biotechnology	25.40%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable

TRDA, JANX, SANA, and KURA Headlines

Recent News About These Companies

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29 at 6:40 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29 at 4:28 AM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27 at 7:22 AM | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 26,522 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Acquires Shares of 4,056,379 Entrada Therapeutics, Inc. $TRDA

August 26, 2026 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for TRDA

August 12, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock